To evaluate the predictive value of De Ritis ratio (DRR), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR) for major postoperative complications following RCC surgery, and to assess their predictive utility in addition to Charlson Comorbidity Index (CCI).
We conducted a multicenter retrospective analysis of patients who underwent surgery for M0 RCC. Primary outcome was occurrence of major complication (Clavien-Dindo>2). Optimal thresholds for DRR, NLR, and PLR were identified using Akaike Information Criterion (AIC). Multivariable logistic regression (MVA) assessed associations between biomarkers and complications, adjusting for CCI, eGFR, tumor size, surgery type, pT/pN stage, R.E.N.A.L. score. Predictive performance was evaluated using Area under Curves (AUC) from ROC curves. Internal validation was performed with 1,000-sample bootstrapping.
Among 4122 patients, 198 (4.8%) experienced major complications [urinary leak (n=90, 35.7% of all major complications), bleeding/hematoma (n=38, 15.1%), cardiac events (n=15, 6.0%)]. AIC identified thresholds of 2.3 for elevated DRR (EDRR), 2.7 for NLR (ENLR), and 200 for PLR (EPLR). 191 (4.6%), 1243 (30.2%), and 684 (16.6%) patients had elevated EDRR, ENL, and EPLR. On MVA, all three biomarkers independently predicted major complications: EDRR [Odds ratio (OR)=3.06, p=0.02], ENLR (OR=1.25, p=0.01), EPLR (OR=1.30, p=0.01). AUCs were 0.63 for CCI alone, 0.77 with additional covariates, 0.85 for the model with all biomarkers. Bootstrapped AUC for the full model was 0.77.
Preoperative DRR, NLR, and PLR improve prediction of major complications after RCC surgery in addition to CCI. Our findings point towards an enhanced model to risk stratify and optimize patient outcomes in RCC surgery.
Urology. 2025 Jun 25 [Epub ahead of print]
Giacomo Musso, Natalie Birouty, Andrea Salonia, Giuseppe Garofano, Mai Dabbas, Margaret F Meagher, Kit L Yuen, Benjamin Baker, Cesare Saitta, Dattatraya Patil, Hajime Tanaka, Masaki Kobayashi, Shohei Fukuda, Francesco Montorsi, Alberto Briganti, Umberto Capitanio, Alessandro Larcher, Giuseppe Rosiello, Yasuhisa Fujii, Viraj A Master, Ithaar H Derweesh
Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: ., Department of Urology, Emory University School of Medicine, Building B Suite 1403 1365-B Clifton Road NE, Atlanta, GA 30322, USA. Electronic address: ., Department of Urology, University of Science Tokyo, 1 Chome-5-45 Yushima, Bunkyo City, Tokyo 113-8510, Japan. Electronic address: ., Department of Urology, University of Science Tokyo, 1 Chome-5-45 Yushima, Bunkyo City, Tokyo 113-8510, Japan. Electronic address: ., Department of Urology, University of Science Tokyo, 1 Chome-5-45 Yushima, Bunkyo City, Tokyo 113-8510, Japan. Electronic address: ., Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele, Via Olgettina 60, Milan, 20132, Italy; Vita-Salute San Raffaele University, Via Olgettina 60, Milan, 20132, Italy. Electronic address: ., Department of Urology, University of Science Tokyo, 1 Chome-5-45 Yushima, Bunkyo City, Tokyo 113-8510, Japan. Electronic address: ., Department of Urology, Emory University School of Medicine, Building B Suite 1403 1365-B Clifton Road NE, Atlanta, GA 30322, USA. Electronic address: ., Department of Urology, UC San Diego School of Medicine, 9400 Campus Point Drive, La Jolla, CA 92037, USA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/40578444